# Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs

> **NCT00227422** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 324 (—)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Mencevax ACWY

## Key facts

- **NCT ID:** NCT00227422
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 324 (—)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227422, "Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00227422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*